VERTEBRATE.ai

Five years ago, Rodney Gorham had a mesh-covered electrode array threaded through his jugular vein and into a blood vessel that runs along the surface of his brain. Today, he uses it to turn on lamps, adjust his thermostat, and otherwise run his house without lifting a finger—literally. Gorham, who lost the use of his hands to ALS, is the longest-surviving recipient of an implant made by Synchron, the Brooklyn-based brain-computer interface company, and his five years of daily use, detailed this week in Wired, have quietly become one of the industry's most important data points: proof that a device can live inside a human skull for half a decade without falling apart, causing infection, or being rejected by the body it inhabits.

That durability question matters more than it might sound, because the field chasing Gorham's outcome is now crowded and fighting over fundamentally different bets on how close to the brain a machine needs to get. Neuralink, Elon Musk's implant company, has drawn the most headlines with its own surgically placed chip, threading thousands of electrodes directly into brain tissue via a robot surgeon, a more invasive approach than Synchron's stent-like device, which avoids open-brain surgery by traveling through blood vessels. A recent comparison of Neuralink against BrainCo, which makes wearable, non-invasive sensors worn like a headband, lays out the industry's real fork in the road: surgery and higher-fidelity signals versus no incisions at all but a fuzzier read on the brain's intentions.

None of these approaches has yet produced a product available at a pharmacy or a Best Buy, and that gap is precisely why Gorham's five years matter so much to people well outside the small circle of BCI patients. Every additional year an implant sits safely in a human body without complications is a year of clinical and regulatory evidence that invasive BCIs can be maintained, not just demonstrated. That evidence shapes how the FDA thinks about approving these devices, how insurers might someday cover them, and how many of the roughly 30,000 Americans living with ALS, along with those paralyzed by stroke or spinal injury, might eventually regain some version of independence.

The competition between invasive and wearable models isn't just an engineering dispute; it's a bet on where the market will actually land. Invasive implants promise richer control—Gorham can operate multiple devices with nuance—but require surgery few people will readily volunteer for outside of severe disability. Wearables like BrainCo's promise easier adoption at the cost of precision, aiming at consumers who'd never agree to a procedure. If BCIs are ever going to move from a handful of trial patients to something resembling a consumer category, both paths will likely coexist, serving very different needs. What Gorham's five years actually prove is more modest than a cure: that the hardware can last, that a life augmented by thought-controlled machines is livable day to day, and that the industry's next real test isn't ambition—it's endurance.